Third Quarter 2026 Financial and Business Highlights (all figures approximate and presented in USD):
Horizon Quantum andOxford Quantum Circuits (“OQC”) announce successful pulse-level integration.Horizon Quantum signed a non-binding letter of intent to acquireEntropica Labs .Horizon Quantum announces the development and implementation of protocols for performing efficient characterization of large quantum processors.- Operating loss for Q3 2026 on an as-reported basis of
$10.5 million compared to$4.9 million for the third fiscal quarter endedSeptember 30, 2025 (“Q3 2025”). - Net Income for Q3 2026 on an as-reported basis of
$33.4 million , or$0.61 per ordinary share, compared to a loss of$5.2 million in Q3 2025, or$0.13 per ordinary share in Q3 of 2025. The Q3 2026 quarter result included a$43.1 million non-cash gain from the remeasurement of warrant-related derivative liabilities driven by a decrease in the Company’s share price. - Adjusted EBITDA was a loss of
$6.3 million in Q3 2026 as compared to a loss of$3.0 million in Q3 2025. - Cash and cash equivalents at the end of Q3 2026 of
$102.8 million , a net decrease of$10.5 million from$113.3 million at the end of the fiscal quarter endedJune 30, 2026 (“Q2 2026”).
CEO Commentary
"During the third quarter of 2026, as part of our ongoing collaboration with OQC, we successfully completed the pulse-level integration of Triple Alpha with their 32 qubit Toshiko quantum processing unit, a further milestone in our aim of tightly integrating our software infrastructure with a variety of hardware platforms. We also announced that we have implemented our proprietary techniques for multiplexed characterization on a processor with greater than 100 qubits for the first time, enabling more efficient, scalable QPU characterization," said
He continued, "In addition we recently signed a non-binding letter of intent to acquire
Operational Highlights
Expanding Horizon Quantum’s Hardware Ecosystem
By tightly integrating its software infrastructure with a variety of hardware platforms,
Horizon Quantum announces the successful pulse-level integration of OQC’s 32- qubit Toshiko quantum processing unit (QPU) with Triple Alpha, Horizon Quantum’s integrated development environment, as part of an ongoing collaboration.- The
Horizon Quantum team used Triple Alpha’s pulse-level control capabilities to access OQC’s superconducting QPU’s control layer and characterize parameters such as qubit relaxation (T1) and qubit phase coherence (T2), which are metrics describing how long a quantum computer can keep information and execute calculations. - As part of the collaboration, Triple Alpha was used to perform gate calibration – executing a high-level quantum program on the OQC QPU.
- Using Triple Alpha, developers can harness pulse-level control within the same programming languages that are used to develop quantum applications.
- Characterization is a key step in preparing quantum hardware for practical use, and because quantum systems are highly sensitive, frequent recalibration is necessary.
- Triple Alpha’s portable approach lets users write programs once and execute them across different control systems. They can create and deploy characterization and calibration routines and integrate them into their workflow via a simple web-based API.
- The
Expanding Horizon Quantum’s Technical Capabilities
By developing software capabilities that enable more accurate, efficient, and scalable hardware characterization and calibration,
Horizon Quantum announces the development of a new protocol for performing multiplex processor characterization across multiple qubits, with results validated against conventional individual pairwise characterization techniques, enabling more efficient, scalable QPU characterization.Horizon Quantum has implemented its proprietary techniques for multiplexed characterization on a processor with greater than 100 qubits for the first time, measuring ZZ crosstalk, where unwanted interactions between qubits can reduce computational fidelity, and extended the techniques to measure control crosstalk, where control signals applied to one qubit have unintended effects on others.- Understanding unintended interactions between qubits is essential for improving QPU performance, but traditional individual pairwise characterization scales quadratically with the number of qubits, requiring large numbers of measurements.
- Multiplexing combines multiple measurements into a smaller number of experiments performed in parallel, significantly reducing characterization overhead.
- On a 100-qubit processor, when compared with conventional pairwise characterization, Horizon Quantum’s multiplexing approach can reduce the number of experiments required to characterize ZZ crosstalk from approximately 5,000 to 7, representing a more than 700-fold reduction, demonstrating how software-driven multiplexing can make QPU characterization more efficient and scalable.
Corporate Update
Third Quarter 2026 Financial Results
All results are presented as approximate and in USD.
- Total operating expenses for Q3 2026 were
$10.5 million compared to$4.9 million for Q3 2025. - Research and development (R&D) expenses for Q3 2026 were
$4.5 million compared to$2.0 million for Q3 2025, representing an increase of 122%. When excluding share-based compensation from each period of$1.7 million and$0.3 million , respectively, the period-over-period increase in R&D expenses was 65% and was primarily attributable to increases in headcount and salary adjustments and to a lesser extent costs from related information technology expenses. - Sales and marketing expenses for Q3 2026 were
$0.4 million , essentially flat period-over-period compared to$0.4 million for Q3 2025. - General and administrative (G&A) expenses for Q3 2026 were
$5.2 million compared to$2.3 million for Q3 2025, representing an increase of 127%. Excluding share-based compensation expenses of$2.0 million and$0.5 million from Q3 2026 and Q3 2025, respectively, G&A expenses increased 82% period over period. The period-over-period increase in G&A expenses was primarily due to increases in headcount, and other operating expenses associated with the transition to a public company. - The operating loss for Q3 2026 was
$10.5 million compared to$4.9 million for Q3 2025, representing an increase of$5.6 million . The widening of the loss was primarily due to increases in expenses associated with transitioning to a public company, increases in research and development headcount, and related operational support costs as compared to the prior-year period. - Net Income for Q3 2026 was
$33.4 million , or$0.61 per ordinary share, compared to a net loss of$5.2 million , or$0.13 per ordinary share, in Q3 2025.- The Q3 2026 result included a
$43.1 million non-cash gain from the remeasurement of warrant-related derivative liabilities. The decrease in the trading price of Horizon Quantum’s Class A ordinary shares during Q3 2026 decreased the fair value of these liabilities, resulting in the accounting gain. This gain did not affect the Company’s cash balance. - All warrants of
Horizon Quantum that remain outstanding will continue to be remeasured at fair value each fiscal quarter. Accordingly, future movements in the trading price of Horizon Quantum’s Class A ordinary shares could result in additional non-cash gains or losses.
- The Q3 2026 result included a
- Since derivative fair-value adjustments can create substantial volatility in reported earnings without affecting underlying operating performance or cash flow, management also evaluates results on an Adjusted EBITDA basis, a non-GAAP measure. Adjusted EBITDA excludes changes in the fair value of derivative liabilities as well as share-based compensation, and non-recurring expenses associated with the business combination. On this basis, the company recorded an Adjusted EBITDA loss of
$6.3 million for Q3 2026 compared with an Adjusted EBITDA loss of$3.0 million in Q3 2025.
Conference Call Information
As previously announced, the company will hold a conference call to discuss its third quarter on
Non-GAAP Financial Measures
To supplement Horizon Quantum’s condensed financial statements presented in accordance with
About
Founded in 2018 by Dr.
Note to Investors Regarding Forward-Looking Statements
This press release includes forward-looking statements. The expectations, estimates, and projections of the businesses of
Condensed consolidated balance sheet (Unaudited) |
|
|
|
|
|
|
|
|
| ||||
(In US$, unless otherwise stated) |
| 2026 |
| 2025 | ||
ASSETS |
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
Cash and cash equivalents |
| $ | 102,788,992 |
| $ | 222,939 |
Prepaid and other current assets |
|
| 12,090,401 |
|
| 746,372 |
Total current assets |
|
| 114,879,393 |
|
| 969,311 |
|
|
|
|
|
|
|
Property and equipment, net |
|
| 3,491,033 |
|
| 3,204,829 |
Intangible assets, net |
|
| 19,633 |
|
| 22,566 |
Right-of-use assets |
|
| 259,476 |
|
| 459,982 |
Other non-current assets |
|
| 111,913 |
|
| 175,115 |
TOTAL ASSETS |
| $ | 118,761,448 |
| $ | 4,831,803 |
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
Derivative liabilities - SAFE |
| $ | - |
| $ | 6,406,878 |
Other payables |
|
| 1,996,723 |
|
| 2,602,604 |
Operating lease liabilities |
|
| 229,551 |
|
| 396,025 |
Total current liabilities |
|
| 2,226,274 |
|
| 9,405,507 |
|
|
|
|
|
|
|
Derivative liabilities - warrants |
|
| 32,412,785 |
|
| - |
Operating lease liabilities, non-current |
|
| 32,416 |
|
| 88,921 |
TOTAL LIABILITIES |
| $ | 34,671,475 |
| $ | 9,494,428 |
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Seed Preferred Shares, 2,500,000 authorized; 2,500,000 issued and outstanding as of |
| $ | - |
| $ | 839,602 |
Seed Plus Preferred Shares, 2,936,828 authorized; 2,936,828 issued and outstanding as of |
|
| - |
|
| 2,349,212 |
Series A Preferred Shares, 2,586,522 authorized; 2,586,522 issued and outstanding as of |
|
| - |
|
| 18,100,000 |
Ordinary Shares, 8,000,000 authorized; 8,000,000 issued and outstanding as of |
|
| - |
|
| 3,649 |
Ordinary Class A Shares, 34,811,740 authorized, 34,811,740 issued and outstanding as of |
|
| 191,735,625 |
|
| - |
Ordinary Class |
|
| 40,110 |
|
| - |
Additional paid-in capital |
|
| 11,083,158 |
|
| 7,417,778 |
Accumulated deficit |
|
| (119,028,107) |
|
| (33,573,537) |
Accumulated other comprehensive (loss) income |
|
| 259,187 |
|
| 200,671 |
TOTAL STOCKHOLDERS’ EQUITY |
| $ | 84,089,973 |
| $ | (4,662,625) |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
| $ | 118,761,448 |
| $ | 4,831,803 |
Note: All results presented prior to the closing of the business combination on | ||||||
Condensed consolidated statement of operations and comprehensive loss (Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
| Nine Months Ended | ||||||||
(In US$, except share amount and per share data) | 2026 |
| 2025 |
| 2026 |
| 2025 | ||||
Revenue | $ | - | $ | - |
| $ | - | $ | 38,462 | ||
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
| 4,457,981 |
|
| 2,010,289 |
|
| 9,200,416 |
|
| 6,537,892 |
Selling and marketing |
| 433,211 |
|
| 372,748 |
|
| 1,268,163 |
|
| 949,413 |
General and administrative |
| 5,222,583 |
|
| 2,302,133 |
|
| 12,673,840 |
|
| 4,349,657 |
Depreciation and amortization |
| 375,083 |
|
| 182,767 |
|
| 1,021,316 |
|
| 532,603 |
Total operating expenses |
| 10,488,857 |
|
| 4,867,937 |
|
| 24,163,735 |
|
| 12,369,566 |
Loss from operations |
| (10,488,857) |
|
| (4,867,937) |
|
| (24,163,735) |
|
| (12,331,104) |
|
|
|
|
|
|
|
|
|
|
|
|
Other income and (expense): |
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
| (2,679) |
|
| (2,021) |
|
| (8,365) |
|
| (6,850) |
Other income |
| 840,058 |
|
| 7,686 |
|
| 1,370,501 |
|
| 57,415 |
Change in fair value of derivative liabilities |
| 43,099,876 |
|
| (317,352) |
|
| (62,217,816) |
|
| (317,352) |
Foreign exchange (loss) |
| (37,002) |
|
| (12,896) |
|
| (355,914) |
|
| (319,823) |
Income tax expense |
| - |
|
| - |
|
| - |
|
| - |
Net income (loss) | $ | 33,411,396 |
| $ | (5,192,520) |
| $ | (85,375,330) |
| $ | (12,917,714) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
| (37,993) |
|
| 28,960 |
|
| 58,516 |
|
| 246,948 |
Total comprehensive income (loss) | $ | 33,373,403 |
| $ | (5,163,560) |
| $ | (85,316,814) |
| $ | (12,670,766) |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average ordinary shares outstanding, as recast |
|
|
|
|
|
|
|
|
|
|
|
Basic |
| 54,345,937 |
|
| 39,015,950 |
|
| 49,230,764 |
|
| 39,015,950 |
Diluted |
| 60,792,710 |
|
| 39,015,950 |
|
| 49,230,764 |
|
| 39,015,950 |
Basic net income (loss) per ordinary share, as recast | $ | 0.61 |
| $ | (0.13) |
| $ | (1.73) |
| $ | (0.33) |
Diluted net income (loss) per ordinary share, as recast | $ | 0.55 |
| $ | (0.13) |
| $ | (1.73) |
| $ | (0.33) |
Note: All results presented prior to the closing of the business combination on | |||||||||||
Condensed consolidated statement of cashflow (Unaudited) |
|
|
|
| |
|
|
|
|
| |
| Nine Months Ended | ||||
(In US$, unless otherwise stated) | 2026 | 2025 | |||
Cash flows from operating activities |
|
|
|
| |
Loss for the period | $ | (85,375,330) | $ | (12,917,714) | |
Adjustments to reconcile net loss to net cash used for operating activities: |
|
|
|
| |
Depreciation |
| 1,018,383 |
| 530,967 | |
Share based compensation |
| 5,655,459 |
| 4,324,494 | |
Change in fair value of derivative liabilities |
| 62,217,816 |
| 286,106 | |
Unrealized foreign currency transaction (gain) loss |
| 75,487 |
| 687,604 | |
Amortization |
| 2,933 |
| 1,636 | |
Changes in operating assets and liabilities: |
|
|
|
| |
Accounts receivable |
| - |
| 270,824 | |
Other payables |
| 663,382 |
| 546,211 | |
Lease liability |
| (322,504) |
| (201,633) | |
Prepaid expenses and other assets |
| (384,575) |
| (514,438) | |
Net cash used in operating activities |
| (16,448,949) |
| (6,985,943) | |
|
|
|
|
| |
Cash flows from investing activities |
|
|
|
| |
Purchase of property, equipment including construction in progress |
| (11,004,556) |
| (392,309) | |
Purchase of intangible assets and trademarks |
| - |
| - | |
Net cash used in investing activities |
| (11,004,556) |
| (392,309) | |
|
|
|
|
| |
Cash flows from financing activities |
|
|
|
| |
Proceeds from issuance of SAFE notes |
| 2,500,000 |
| 3,000,000 | |
Proceeds from exercise of warrants |
| 28,688,913 |
| - | |
Proceeds from exercise of employee stock options |
| 712,993 |
| - | |
Proceeds from merger and PIPE transaction, net of transaction costs |
| 98,167,633 |
| - | |
Net cash provided by financing activities |
| 130,069,540 |
| 3,000,000 | |
Effect of exchange rate changes on cash |
| (49,982) |
| (184,701) | |
Net increase (decrease) in cash and cash equivalents |
| 102,566,053 |
| (4,562,953) | |
Cash and cash equivalents at beginning of period |
| 222,939 |
| 4,848,855 | |
Cash and cash equivalents at end of period | $ | 102,788,992 | $ | 285,902 | |
Supplemental disclosures of non-cash transactions: |
|
|
|
| |
Initial recognition of warrant liabilities at close of the business combination | $ | 20,526,410 |
| - | |
Initial recognition of net assets at close of the business combination | $ | 2,458,713 |
| - | |
Conversion of SAFE liabilities into equity at close of the business combination | $ | 11,183,077 |
| - | |
Issuance of shares to a service provider | $ | 269,000 |
| - | |
Reclassification of warrant liabilities to equity upon exercise | $ | 48,055,242 |
| - | |
Reclassification of share based payment reserve to equity upon exercise | $ | 1,218,248 |
| - | |
Note: All results presented prior to the closing of the business combination on | |||||
Reconciliation of Non-GAAP Financial Measures | |||||||||||
Below is a reconciliation of net loss (GAAP) to adjusted EBITDA: | |||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||
(In US$, unless otherwise stated) | 2026 |
| 2025 |
| 2026 |
| 2025 | ||||
Net income (loss) (GAAP) | $ | 33,411,396 |
| $ | (5,192,520) |
| $ | (85,375,330) |
| $ | (12,917,714) |
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
Net interest (income) expense |
| (835,048) |
|
| (5,429) |
|
| (1,347,826) |
|
| (48,344) |
Depreciation and amortization expenses |
| 375,083 |
|
| 182,767 |
|
| 1,021,316 |
|
| 532,603 |
EBITDA |
| 32,951,431 |
|
| (5,015,182) |
|
| (85,701,840) |
|
| (12,433,454) |
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
Share based compensation within |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
| 1,707,190 |
|
| 338,080 |
|
| 2,384,171 |
|
| 3,116,688 |
Selling and marketing |
| 51,444 |
|
| 52,657 |
|
| 143,830 |
|
| 223,106 |
General and administrative |
| 2,018,462 |
|
| 546,282 |
|
| 2,858,456 |
|
| 983,957 |
Change in fair value of derivative liabilities |
| (43,099,876) |
|
| 317,352 |
|
| 62,217,816 |
|
| 317,352 |
Business combination and post-closing expenses* |
| 30,664 |
|
| 753,901 |
|
| 2,195,594 |
|
| 968,003 |
Adjusted EBITDA | $ | (6,340,686) |
| $ | (3,006,910) |
| $ | (15,901,971) |
| $ | (6,824,349) |
*Includes | |||||||||||
Note: All results presented prior to the closing of the business combination on | |||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20261110949593/en/
Investor Contact
investors@horizonquantum.com
Media Contact
Yanina Blaclard
media@horizonquantum.com
Source: